 
Bio Stem Technologies Accelerates Into 2026 With Transformative Acquisition, Seven Straight Profitable Quarters, and Entry into Advanced and Acute Wound Care Markets! BioStem Technologies (OTCQB: BSEM) is emerging as one of the most compelling small-cap MedTech companies as 2026 begins. The company just completed the acquisition of BioTissue Holdings’ surgical and wound care business, instantly expanding its footprint into hospital-based, acute, and surgical wound care. With established product lines like Neox® and Clarix®, a nationwide sales force, and key GPO contracts, BioStem is now positioned to capture a $300–$350 million addressable market, spanning chronic and acute wound care, burns, and soft-tissue repair. Zacks Small Cap Research has assigned BSEM a $25.50 price target, highlighting confidence in the company’s profitable growth, clinical validation, and expanding market presence. Coupled with seven consecutive profitable quarters, strong gross margins of 88.5%, and $16 million in cash post-acquisition, BSEM is demonstrating operational excellence rarely seen in small-cap regenerative medicine. Backed by clinically validated BioREtain® technology, FDA-level studies, and a potential Nasdaq uplisting in mid-2026, BSEM is gaining traction with both institutional investors and healthcare providers. Discover why BSEM is setting the standard for profitable, clinically proven MedTech growth in 2026
Special Report The Time to Buy ServiceNow Is Now: Oversold and Ready for a ReboundReported by Thomas Hughes. Date Posted: 1/31/2026. 
Key Takeaways- ServiceNow looks set up for a 2026 rebound and may just need one clear catalyst to bring retail buyers back.
- Institutions are buying into the pullback in early 2026, treating it as a value-driven entry point.
- Cash flow and growth execution support the outlook, with recent equity gains reinforcing the longer-term case.
Valuation concerns capped ServiceNow (NYSE: NOW) price action in 2025, producing a correction that has created a buying opportunity in 2026. The Q4 release affirmed the company's strengths, its longer-term outlook and increasing value. Trading at roughly 30x near-term earnings and about 15x the 2030 outlook, the stock could deliver a solid double-digit — even triple-digit — price advance over the next several years. Institutional activity is another factor supporting the early-2026 opportunity. Investors sold on balance in Q4 2025 to harvest losses, but were net buyers for the year and accelerated purchases in early 2026. January buying topped $6 billion, or roughly 4% of the market cap, and is likely to remain substantial given the valuation opportunity. There are 90 paper gold claims for every real ounce in COMEX vaults. Ninety promises, one ounce of metal. It's like musical chairs with 90 players and one chair. COMEX gold inventory dropped 25 percent last year alone as gold flows East to Shanghai, Mumbai, and Moscow. On March 31st, contract holders can demand delivery. When similar situations arose in the past, markets closed and rules changed. Paper holders got crushed while mining stock holders made fortunes. One stock sits at the center of this crisis. Get the full story on this opportunity now. Highlights from the Q4 release include a $5 billion increase to the buyback authorization. The repurchases are focused on offsetting dilution and are meaningful for long-term holders. While ServiceNow does not aggressively repurchase shares or pay a dividend, it continues to invest heavily in growth and delivered a 35% equity gain in 2025. The year-end balance sheet shows the company is well positioned to continue executing its strategy, and the 2026 outlook suggests another double-digit gain may be ahead. Generative AI Drives Q4 Strength for ServiceNowServiceNow reported a solid quarter, with revenue growing more than 20% to over $3.5 billion. The strength was driven by subscriptions, which rose 21% year-over-year, supported by agentic and generative AI tools and client expansion. The Now Assist generative AI offering more than doubled year-over-year, while net new contract volume for deals over $1 million grew roughly 40%. Margin trends were also favorable despite the market's immediate reaction. The company delivered margin expansion driven by revenue leverage and operational execution, leaving adjusted EPS of $0.92 — $0.03 ahead of the MarketBeat consensus — alongside a robust 2026 outlook. Management guided revenue growth to moderate into the high-teens to low-20s, which remains above consensus and is likely conservative given a 25% increase in current remaining performance obligations (cRPO) and a 26.5% rise in total RPO. That RPO build suggests upside to growth could materialize in 2026. ServiceNow Stock Overextends, Diverges From IndicatorsThe stock plunged more than 10% after the Q4 release and guidance update and could see further near-term weakness. However, technical indicators — including stochastic oscillators and MACD — show significant divergence, which often signals overextension and a higher probability of a rebound. In this scenario, NOW could find a bottom in early 2026 and set up for recovery later in the year. The December stock split also influenced market action, since splits often create short-term selling opportunities for investors. Historically, companies that split their shares tend to have strong underlying businesses, healthy cash flow and shareholder-friendly capital policies, and they frequently trend higher over longer timeframes. That suggests current selling pressure may eventually give way to renewed accumulation. The likely catalyst for a sustained rebound will be upcoming quarterly results. Continued operational strength could prompt analysts to adopt a more bullish stance and entice retail investors back into the market. For now, analysts have trimmed price targets on this Moderate Buy-rated stock toward the lower end of the range — roughly where the shares are trading today — which provides a nearby technical floor of support. 
This message is a paid advertisement for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency and Huge Alerts. American Consumer News, LLC dba MarketBeat receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $12,600. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Sideways Frequency or Huge Alerts. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts' website for additional information about the relationship between Huge Alerts and BioStem Technologies Inc. (OTC: BSEM). | 
No comments:
Post a Comment